<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med Genet</journal-id><journal-title>BMC Medical Genetics</journal-title><issn pub-type="epub">1471-2350</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2350-2-8</article-id><article-id pub-id-type="pmid">11495633</article-id><article-id pub-id-type="doi">10.1186/1471-2350-2-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Apolipoprotein E gene polymorphism is not a strong risk factor for diabetic nephropathy and retinopathy in Type I diabetes: case-control study</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Shcherbak</surname><given-names>Natalia S</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>nshch@yahoo.com</email></contrib></contrib-group><aff id="I1"><label>1</label>St.Petersburg State Medical University, Laboratory of Molecular Cardiology, L.Tolstoy St. 6/8, St.Petersburg, 197189, Russia</aff><pub-date pub-type="collection"><year>2001</year></pub-date><pub-date pub-type="epub"><day>24</day><month>7</month><year>2001</year></pub-date><volume>2</volume><fpage>8</fpage><lpage>8</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/2/8"/><history><date date-type="received"><day>10</day><month>3</month><year>2001</year></date><date date-type="accepted"><day>24</day><month>7</month><year>2001</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2001 Shcherbak; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.</copyright-statement><copyright-year>2001</copyright-year><copyright-holder>Shcherbak; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.</copyright-holder></permissions><abstract><sec><title>Background</title><p>The gene encoding apolipoprotein E (<italic>APOE</italic>) has been proposed as a candidate gene for vascular complications in Type I diabetes. This study aimed to investigate the influence of three-allelic variations in the <italic>APOE</italic> gene for the development of diabetic retinopathy and nephropathy.</p></sec><sec><title>Results</title><p>Neither <italic>APOE</italic> alleles frequencies or <italic>APOE</italic> genotypes frequencies differed between Type I diabetic groups either with or without nephropathy. Similar results were found for patients with and without diabetic retinopathy.</p></sec><sec><title>Conclusions</title><p><italic>APOE</italic> gene polymorphism does not determine genetic susceptibility for the development of diabetic retinopathy in Type I diabetes patients. Association between <italic>APOE</italic> gene polymorphism and diabetic nephropathy may be weak or moderate, but not strong.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Familial and epidemiological studies have indicated that there is a strong genetic component in the aetiology of diabetic nephropathy in Type I diabetes patients [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. Apolipoprotein E (apoE) was discovered as a plasma protein involved in the metabolism of lipoproteins. Recently, the apolipoprotein E (<italic>APOE</italic>) gene has been suggested to be a risk factor for the development of micro- and macrovascular complications in diabetic patients.</p><p>The <italic>APOE</italic> gene is polymorphic. There are three common alleles, <italic>E2, E3,</italic> and <italic>E4,</italic> which code for three major isoforms, resulting in six common genotypes [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>]. Individuals with apoE2 have higher triglyceride levels and are associated with lower cholesterol compared to individuals with apoE3. Individuals with apoE4 often have elevated plasma cholesterol levels. There is an increased prevalence of cardiovascular disease and particularly Alzheimer's disease [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>].</p><p>Apolipoprotein E polymorphism may influence the metabolism of lipoproteins in diabetic patients. Several recent studies have suggested that this polymorphism may be associated with a genetic predisposition for diabetic nephropathy [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. Thus, <italic>APOE</italic> is an important candidate gene for the development of microvascular complications in Type I diabetes patients.</p><p>The aim of this study was to investigate the influence of <italic>APOE</italic> gene polymorphism in the development of diabetic nephropathy and retinopathy in Type I diabetes patients.</p></sec><sec sec-type="materials|methods"><title>Materials and Methods</title><sec><title>Patients</title><p>In this study, all patients were Russians with unrelated Type I diabetes. All diabetic patients for the case-control study were recruited from St.Petersburg Diabetological Centres and had participated in the program "Diabetes mellitus" (which included monitoring of trends and examinations of the determinants of vascular complications in Type I diabetes) carried out in St. Petersburg, Russia since 1997.</p><p>The diabetic patients included in this study satisfied the World Health Organization criteria for diabetes mellitus [<xref ref-type="bibr" rid="B12">12</xref>]. Glycated haemoglobin (HbAlc) was measured by ion exchange chromatography [<xref ref-type="bibr" rid="B13">13</xref>]. At entry the patients had HbAlc levels of 5.7 to 16.8%.</p><p>The Type I diabetes groups consisted of 74 subjects with nephropathy and 92 subjects without. The study covered 76 Type I diabetes patients with diabetic retinopathy and 96 patients without. Some subjects had more than one type of diabetic complication, and consequently were analysed in more than one group.</p><p>For Type I diabetes patients, all the information was examined for evidence of nondiabetic renal disease. Then questionnaires, medical records, and measurements of albumin excretion were used to determine whether they had diabetic nephropathy. Those patients were considered to have diabetic nephropathy if they were receiving treatment for renal disease and either suffered from persisting proteinuria, or had persisting high albuminuria. Urinary albumin excretion was measured by nephelometry [<xref ref-type="bibr" rid="B14">14</xref>]. Nephropathy was defined as a persistent urinary albumin excretion of more than 20 &#x003bc;g/min, or 30 mg/24 h in two out of three consecutive urinalyses. Individuals with no history of nephropathy and no albumin excretion were considered free of nephropathy.</p><p>Fundus ophthalmoscopy and angiofluorography were used to diagnose retinopathy. The diabetic retinopathy group consisted of those showing retinal change, while Type I diabetes control group were those who showed no signs of retinopathy.</p></sec><sec><title>DNA genotyping</title><p>Blood was collected from each individual and stored in ethylenediaminetetraacetic acid (EDTA) tubes at -20&#x000b0;C. Genomic DNA was obtained from lysed white blood cells by phenol-chloroform extraction. The <italic>APOE</italic> gene polymorphism was detected by polymerase chain reaction (PCR). <italic>APOE</italic> genotyping was performed by the method of Hixson and Vernier [<xref ref-type="bibr" rid="B15">15</xref>] using a modified version described by Skobeleva et al. [<xref ref-type="bibr" rid="B16">16</xref>].</p><p>The sequence of the sense oligonucleotide primer was 5'-AGATGCGGGCACGGCTGTTCAAGGA-3', and the antisense primer was 5'-CCCTCGCGAGCCCCGGCCTGGTACAC-3' [<xref ref-type="bibr" rid="B16">16</xref>]. Each amplification reaction contained 50 mM KCl, 10 mM tris-HCl pH 8.4, 1.5 mM MgCl<sub>2</sub>, 0.25 &#x003bc;M of each primer, 200 &#x003bc;M dNTP, 10% DMSO, 0.1 &#x003bc;g DNA and 1 U Tag polymerase in a final volume of 20 &#x003bc;l. After denaturation step at 95&#x000b0;C for 5 minutes followed by 30 cycle of denaturation at 92&#x000b0;C (1 min), annealing at 64&#x000b0;C (1 min), extension at 72&#x000b0;C (1.5 min) and a final extension at 72&#x000b0;C (5 min) using a MiniCycler (MJ Research, Watertown, MA, USA). Genotypes were determined by <italic>Hin6</italic>1 (Fermentas, Vilnius, Lithuania) digestion of a 244-base pair PCR-amplified fragment spanning the two polymorphic sites. The digested DNA fragments were separated using migration on 12% polyacrylamide gels and visualized under UV illumination after ethidium bromide staining [<xref ref-type="bibr" rid="B16">16</xref>]. The codominant alleles <italic>E2, E3,</italic> and <italic>E4</italic> determine the six <italic>APOE</italic> genotypes.</p></sec><sec><title>Statistical testing</title><p>All data are presented as means &#x000b1; SD. Groups were compared using the Student's <italic>t</italic> test for comparison of two groups for quantitative variables. Allele frequency among control subjects and case subjects were compared using standard &#x003a7;<sup>2</sup> tests. The difference in genotype frequencies between the groups was tested by Fisher's exact test. A value of P &#x0003c; 0.05 was considered significant.</p></sec></sec><sec><title>Results</title><p>Clinical characteristics by study group are shown in Table <xref ref-type="table" rid="T1">1</xref>. No significant difference was seen between groups with vascular complications (nephropathy and retinopathy) and those without, no matter the age, diabetes duration, age at diabetes onset, and mean HbAlc.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Clinical characteristics by study groups</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center">Type I diabetes</td><td align="center">Type I diabetes</td><td align="center">Type I diabetes</td><td align="center">Type I diabetes</td></tr><tr><td></td><td align="center">subjects</td><td align="center">subjects</td><td align="center">subjects</td><td align="center">subjects</td></tr><tr><td></td><td align="center">with</td><td align="center">without</td><td align="center">with</td><td align="center">without</td></tr><tr><td></td><td align="center">nephropathy</td><td align="center">nephropathy</td><td align="center">retinopathy</td><td align="center">retinopathy</td></tr><tr><td></td><td align="center">(DN+)</td><td align="center">(DN-)</td><td align="center">(DR+)</td><td align="center">(DR-)</td></tr></thead><tbody><tr><td align="center">Total subjects</td><td align="center">74</td><td align="center">92</td><td align="center">76</td><td align="center">96</td></tr><tr><td align="center">Age (years)</td><td align="center">25.1 &#x000b1; 11.9</td><td align="center">20.8 &#x000b1; 8.7</td><td align="center">29.8 &#x000b1; 10.1</td><td align="center">22.9 &#x000b1; 9.1</td></tr><tr><td align="center">Sex</td><td></td><td></td><td></td><td></td></tr><tr><td align="center">(male/female)</td><td align="center">40/34</td><td align="center">40/52</td><td align="center">34/42</td><td align="center">50/46</td></tr><tr><td align="center">Diabetes</td><td></td><td></td><td></td><td></td></tr><tr><td align="center">duration</td><td align="center">14.8 &#x000b1; 8.8</td><td align="center">10.9 &#x000b1; 4.3</td><td align="center">17.4 &#x000b1; 8.6</td><td align="center">11.2 &#x000b1; 3.1</td></tr><tr><td align="center">(years)</td><td></td><td></td><td></td><td></td></tr><tr><td align="center">Diabetes onset</td><td></td><td></td><td></td><td></td></tr><tr><td align="center">(years)</td><td align="center">11.1 &#x000b1; 6.2</td><td align="center">10.3 &#x000b1; 6.8</td><td align="center">12.2 &#x000b1; 8.1</td><td align="center">11.5 &#x000b1; 5.2</td></tr><tr><td align="center">HbA1c(%)</td><td align="center">10.5 &#x000b1; 2.2</td><td align="center">9.8 &#x000b1; 1.9</td><td align="center">10.6 &#x000b1; 1.7</td><td align="center">9.9 &#x000b1; 1.7</td></tr></tbody></table><table-wrap-foot><p>Data are means &#x000b1; SD</p></table-wrap-foot></table-wrap><p>The frequency of each genotype in each group conformed to the Hardy -Weinberg equilibrium.</p><p>The distribution of the <italic>APOE</italic> genotypes is shown in Table <xref ref-type="table" rid="T2">2</xref>. There was no significant difference in <italic>APOE</italic> genotype and allele frequency between nephropathic and normoalbuminuric diabetic patients. In this study, no association was found between diabetic retinopathy and <italic>APOE</italic> polymorphisms. <italic>APOE</italic> allele frequencies for males and females were similar within groups and in different groups.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Distribution<italic>of APOE</italic> genotypes and alleles in the case-control association study</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center">Type I</td><td align="center">Type I</td><td align="center">P</td><td align="center">Type I</td><td align="center">Type I</td><td align="center">P</td></tr><tr><td></td><td align="center">diabetes</td><td align="center">diabetes</td><td align="center">value</td><td align="center">diabetes</td><td align="center">diabetes</td><td align="center">Value</td></tr><tr><td></td><td align="center">subjects</td><td align="center">subjects</td><td></td><td align="center">subjects</td><td align="center">subjects</td><td></td></tr><tr><td></td><td align="center">with</td><td align="center">without</td><td></td><td align="center">with</td><td align="center">without</td><td></td></tr><tr><td></td><td align="center">nephropathy</td><td align="center">nephropathy</td><td></td><td align="center">retinopathy</td><td align="center">retinopathy</td><td></td></tr><tr><td></td><td align="center">(DN+)</td><td align="center">(DN-)</td><td></td><td align="center">(DR+)</td><td align="center">(DR-)</td><td></td></tr><tr><td></td><td align="center">n (%)</td><td align="center">n (%)</td><td></td><td align="center">n (%)</td><td align="center">n (%)</td><td></td></tr><tr><td></td><td align="center">m/f (%/%)</td><td align="center">m/f (%/%)</td><td></td><td align="center">m/f (%/%)</td><td align="center">m/f (%/%)</td><td></td></tr></thead><tbody><tr><td></td><td align="center">74 (100)</td><td align="center">92(100)</td><td></td><td align="center">76 (100)</td><td align="center">96(100)</td><td></td></tr><tr><td align="center">Total subjects</td><td align="center">40/34</td><td align="center">40/52</td><td></td><td align="center">34/42</td><td align="center">50/46</td><td></td></tr><tr><td></td><td align="center">(54.0/46.0)</td><td align="center">(43.5/56.5)</td><td></td><td align="center">(44.7/55.3)</td><td align="center">(52.1/47.9)</td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td></td><td></td><td align="center">2(2.2)</td><td></td><td></td><td align="center">1(1.0)</td><td></td></tr><tr><td align="center"><italic>E2E2</italic></td><td align="center">0</td><td align="center">0/2</td><td align="center">NS</td><td align="center">0</td><td align="center">0/1</td><td align="center">NS</td></tr><tr><td></td><td></td><td align="center">(0/3.8)</td><td></td><td></td><td align="center">(0/2.2)</td><td></td></tr><tr><td></td><td align="center">48(64.9)</td><td align="center">54(58.7)</td><td></td><td align="center">45(59.2)</td><td align="center">61(63.6)</td><td></td></tr><tr><td align="center"><italic>E3E3</italic></td><td align="center">25/23</td><td align="center">27/27</td><td align="center">NS</td><td align="center">21/24</td><td align="center">33/28</td><td align="center">NS</td></tr><tr><td></td><td align="center">(62.5/67.6)</td><td align="center">(67.5/51.9)</td><td></td><td align="center">(61.8/57.1)</td><td align="center">(66.9/60.9)</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td align="center">1(1.0)</td><td></td></tr><tr><td align="center"><italic>E4E4</italic></td><td align="center">0</td><td align="center">0</td><td align="center">NS</td><td align="center">0</td><td align="center">0/1</td><td align="center">NS</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td align="center">(0/2.2)</td><td></td></tr><tr><td></td><td align="center">13(17.6)</td><td align="center">20(21.7)</td><td></td><td align="center">18(23.7)</td><td align="center">16(16.7)</td><td></td></tr><tr><td align="center"><italic>E2E3</italic></td><td align="center">8/5</td><td align="center">5/15</td><td align="center">NS</td><td align="center">9/9</td><td align="center">6/10</td><td align="center">NS</td></tr><tr><td></td><td align="center">(20.0/14.7)</td><td align="center">(12.5/28.8)</td><td></td><td align="center">(26.4/21.4)</td><td align="center">(12.0/21.7)</td><td></td></tr><tr><td></td><td align="center">3(4.0)</td><td></td><td></td><td align="center">3(3.9)</td><td align="center">1(1.0)</td><td></td></tr><tr><td align="center"><italic>E2E4</italic></td><td align="center">0/3</td><td align="center">0</td><td align="center">NS</td><td align="center">0/3</td><td align="center">1/0</td><td align="center">NS</td></tr><tr><td></td><td align="center">(0/8.9)</td><td></td><td></td><td align="center">(0/7.2)</td><td align="center">(2.0/0)</td><td></td></tr><tr><td></td><td align="center">10(13.5)</td><td align="center">16(17.4)</td><td></td><td align="center">10(13.2)</td><td align="center">16(16.7)</td><td></td></tr><tr><td align="center"><italic>E3E4</italic></td><td align="center">7/3</td><td align="center">8/8</td><td align="center">NS</td><td align="center">4/6</td><td align="center">10/6</td><td align="center">NS</td></tr><tr><td></td><td align="center">(17.5/8.8)</td><td align="center">(20.0/15.5)</td><td></td><td align="center">(11.8/14.3)</td><td align="center">(20.0/13.0)</td><td></td></tr><tr><td></td><td align="center">16(10.8)</td><td align="center">24(13.0)</td><td></td><td align="center">21(13.8)</td><td align="center">19(9.9)</td><td></td></tr><tr><td align="center"><italic>E2</italic></td><td align="center">8/8</td><td align="center">5/19</td><td align="center">NS</td><td align="center">9/12</td><td align="center">7/12</td><td align="center">NS</td></tr><tr><td></td><td align="center">(10.0/11.8)</td><td align="center">(6.3/18.3)</td><td></td><td align="center">(13.2/14/3)</td><td align="center">(7.0/13.0)</td><td></td></tr><tr><td></td><td align="center">119(80.4)</td><td align="center">144(78.3)</td><td></td><td align="center">118(77.6)</td><td align="center">154(80.2)</td><td></td></tr><tr><td align="center"><italic>E3</italic></td><td align="center">65/54</td><td align="center">67/77</td><td align="center">NS</td><td align="center">55/63</td><td align="center">82/72</td><td align="center">NS</td></tr><tr><td></td><td align="center">(81.3/79.4)</td><td align="center">(83.7/74.0)</td><td></td><td align="center">(80.9/75.0)</td><td align="center">(82.0/78.3)</td><td></td></tr><tr><td></td><td align="center">13(8.8)</td><td align="center">16(8.7)</td><td></td><td align="center">13(8.6)</td><td align="center">19(9.9)</td><td></td></tr><tr><td align="center"><italic>E4</italic></td><td align="center">7/6</td><td align="center">8/8</td><td align="center">NS</td><td align="center">4/9</td><td align="center">11/8</td><td align="center">NS</td></tr><tr><td></td><td align="center">(8.7/8.8)</td><td align="center">(10.0/7.7)</td><td></td><td align="center">(5.9/10.7)</td><td align="center">(11.0/8.7)</td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="center">Total</td><td align="center">148 (100)</td><td align="center">184(100)</td><td></td><td align="center">152(100)</td><td align="center">192(100)</td><td></td></tr><tr><td align="center">chromosomes</td><td align="center">80/68</td><td align="center">40/104</td><td></td><td align="center">68/84</td><td align="center">100/92</td><td></td></tr><tr><td></td><td align="center">(54.1/45.9)</td><td align="center">(43.5/56.5)</td><td></td><td align="center">(44.7/55.3)</td><td align="center">(52.1/47.9)</td><td></td></tr></tbody></table><table-wrap-foot><p>NS, not significant (P value &#x0003e; 0.05)</p></table-wrap-foot></table-wrap></sec><sec><title>Discussion</title><p>Diabetic nephropathy and diabetic retinopathy are the two most important microangiopathic complications in Type I diabetic patients. Many of the environmental factors that influence the risk of vascular disease are known, but genetic components of the risk for diabetic microangiopathy are poorly understood. Several candidate genes have been investigated to elucidate the genetic factors responsible for vascular complications. The most important of these are the aldose reductase gene (<italic>ALR2</italic>) [<xref ref-type="bibr" rid="B17">17</xref>], the insertion/deletion (I/D) polymorphism of the angiotensin I &#x02013; converting enzyme (<italic>ACE</italic>) gene [<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref>], C825T polymorphism of the gene encoding the beta-3 subunit of geterotrimeric G-proteins (<italic>GNB3</italic>) [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref>], and C677T polymorphism of the methylenetetrahydrofolate reductase gene (<italic>MTHFR</italic>) [<xref ref-type="bibr" rid="B23">23</xref>].</p><p>The genetic polymorphism of apolipoprotein E is associated with lipid abnormalities. Eto et al. [<xref ref-type="bibr" rid="B9">9</xref>] suggested that lipid abnormalities may contribute to the development and progression of kidney disease, including diabetic nephropathy. The <italic>E2</italic> allele frequency was significantly higher in Type II diabetes patients with nephropathy (7.2%) and with renal failure (9.7%) than in diabetic patients without nephropathy (2.6%) [<xref ref-type="bibr" rid="B9">9</xref>]. Apolipoprotein E polymorphism is associated with the progression of diabetic nephropathy. Presence of the apolipoprotein <italic>E4</italic> allele is a protective factor, and other alleles entail risk factors [<xref ref-type="bibr" rid="B24">24</xref>].</p><p>The genes responsible for genetic predisposition to vascular complications are still unknown, and little is known about the molecular basis of these complications. The influence of the <italic>APOE</italic> gene polymorphism to the development of diabetic microangiopathy is uncertain. Chowdhury et al. [<xref ref-type="bibr" rid="B10">10</xref>] and Araki et al. [<xref ref-type="bibr" rid="B11">11</xref>] demonstrated an association between the presence of the <italic>APOE E2</italic> allele and diabetic nephropathy in Caucasian patients with Type I diabetes, although some investigators do not support this association [<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B26">26</xref>].</p><p>This study elucidated the role of <italic>APOE</italic> gene polymorphism in the predisposition to diabetic vascular complications. No association of<italic>APOE</italic> gene polymorphism with diabetic nephropathy was demonstrated. This result for diabetic nephropathy confirms the findings of Tarnow et al. [<xref ref-type="bibr" rid="B25">25</xref>] and Onuma et al. [<xref ref-type="bibr" rid="B26">26</xref>]. It should be mentioned that sample sizes in [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>] were larger than in this study. With increased sample size comes the possibility to demonstrate an association. But the larger the necessary and sufficient minimal sample size, the weaker the association demonstrated.</p><p>We also analysed the association of the <italic>APOE</italic> gene polymorphism with diabetic retinopathy in the present study. No significant differences were found between groups with and without this vascular complication. A similar result has been shown by Tarnow et al. [<xref ref-type="bibr" rid="B25">25</xref>] for diabetic retinopathy.</p></sec><sec><title>Conclusions</title><p>The present study found no evidence for a role of the <italic>APOE</italic> gene polymorphism in genetic susceptibility for the development of diabetic retinopathy in Type I diabetes patients. Association between <italic>APOE</italic> gene polymorphism and diabetic nephropathy may be weak or moderate, but not strong.</p></sec><sec><title>COMPETING INTERESTS</title><p>None declared.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/content/backmatter/1471-2350-2-8-b1.pdf"/></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>This work was supported by grant M00-2.6K-359 from Competitive Centre of Basic Science (St.Petersburg, Russia).</p><p>The author thanks Dr. A.S.Stroikova (St.Petersburg Diabetic Centre, St.Petersburg, Russia) for her valuable consultation and verification of patients' clinical information.</p><p>The author can not but mention agitated discussions with Prof. E.I.Schwartz (St.Petersburg Paediatric Medical Academy, St.Petersburg, Russia).</p><p>The author wishes to thank reviewers Dr. S.Bain and Dr. A.Demaine for careful reading and helpful comments on the manuscript.</p><p>Special thanks to J.Fletcher (Redraft.com, Maidenhead, UK) for redrafting in part and H.Kidd, Ph.D. (Bioscience Editors &#x02013; GWE, Akarp, Sweden) for editing in part.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>AR</given-names></name><name><surname>Christiansen</surname><given-names>JS</given-names></name><name><surname>Andersen</surname><given-names>JK</given-names></name><name><surname>Kreiner</surname><given-names>S</given-names></name><name><surname>Deckert</surname><given-names>T</given-names></name></person-group><article-title>Diabetic nephropathy in Type 1 (insulin dependent) diabetes: an epidemiological study</article-title><source>Diabetologia</source><year>1983</year><volume>25</volume><fpage>496</fpage><lpage>501</lpage><pub-id pub-id-type="pmid">6363177</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Quinn</surname><given-names>M</given-names></name><name><surname>Angelico</surname><given-names>MC</given-names></name><name><surname>Warram</surname><given-names>JH</given-names></name><name><surname>Krolewski</surname><given-names>AS</given-names></name></person-group><article-title>Familial factors determine the development of diabetic nephropathy in patients with IDDM</article-title><source>Diabetologia</source><year>1996</year><volume>39</volume><fpage>940</fpage><lpage>945</lpage><pub-id pub-id-type="pmid">8858216</pub-id><pub-id pub-id-type="doi">10.1007/s001250050535</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Utermann</surname><given-names>G</given-names></name><name><surname>Langenbeck</surname><given-names>U</given-names></name><name><surname>Beisiegel</surname><given-names>U</given-names></name><name><surname>Weber</surname><given-names>W</given-names></name></person-group><article-title>Genetics of the apolipoprotein E system in man</article-title><source>Am J Hum Genet</source><year>1980</year><volume>32</volume><fpage>339</fpage><lpage>347</lpage><pub-id pub-id-type="pmid">7386461</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zannis</surname><given-names>VI</given-names></name><name><surname>Breslow</surname><given-names>JL</given-names></name></person-group><article-title>Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification</article-title><source>Biochemistry</source><year>1981</year><volume>20</volume><fpage>1033</fpage><lpage>1041</lpage><pub-id pub-id-type="pmid">6260135</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reilly</surname><given-names>SL</given-names></name><name><surname>Ferrell</surname><given-names>RE</given-names></name><name><surname>Kottke</surname><given-names>BA</given-names></name><name><surname>Kamboh</surname><given-names>MI</given-names></name><name><surname>Sing</surname><given-names>CF</given-names></name></person-group><article-title>The gender-specific apolipoprotein E genotype influence on the distribution of lipids and apolipoproteins in the population of Rochester, MN. I. Pleiotropic effects on means and variances</article-title><source>Am J Hum Genet</source><year>1991</year><volume>49</volume><fpage>1155</fpage><lpage>1166</lpage><pub-id pub-id-type="pmid">1842218</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xhignesse</surname><given-names>M</given-names></name><name><surname>Lussier-Cacan</surname><given-names>S</given-names></name><name><surname>Sing</surname><given-names>CF</given-names></name><name><surname>Kessling</surname><given-names>AM</given-names></name><name><surname>Davignon</surname><given-names>J</given-names></name></person-group><article-title>Influences of common variants of apolipoprotein E on measures of lipid metabolism in a sample selected for health</article-title><source>Arterioscler Thromb</source><year>1991</year><volume>11</volume><fpage>1100</fpage><lpage>1110</lpage><pub-id pub-id-type="pmid">2065031</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bickeboller</surname><given-names>H</given-names></name><name><surname>Campion</surname><given-names>D</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name><name><surname>Amouyel</surname><given-names>P</given-names></name><name><surname>Hannequin</surname><given-names>D</given-names></name><name><surname>Didierjean</surname><given-names>0</given-names></name><name><surname>Penet</surname><given-names>C</given-names></name><name><surname>Martin</surname><given-names>C</given-names></name><name><surname>Perez-Tur</surname><given-names>J</given-names></name><name><surname>Michon</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex</article-title><source>Am J Hum Genet</source><year>1997</year><volume>60</volume><fpage>439</fpage><lpage>446</lpage><pub-id pub-id-type="pmid">9012418</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ukkola</surname><given-names>0</given-names></name><name><surname>Kervinen</surname><given-names>K</given-names></name><name><surname>Salmela</surname><given-names>PI</given-names></name><name><surname>von</surname><given-names>DickhoffK</given-names></name><name><surname>Laakso</surname><given-names>M</given-names></name><name><surname>Kesaniemi</surname><given-names>YA</given-names></name></person-group><article-title>Apolipoprotein E phenotype is related to macro- and microangiopathy in patients with non-insulin-dependent diabetes mellitus</article-title><source>Atherosclerosis</source><year>1993</year><volume>101</volume><fpage>9</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">8216506</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eto</surname><given-names>M</given-names></name><name><surname>Horita</surname><given-names>K</given-names></name><name><surname>Morikawa</surname><given-names>A</given-names></name><name><surname>Nakata</surname><given-names>H</given-names></name><name><surname>Okada</surname><given-names>M</given-names></name><name><surname>Saito</surname><given-names>M</given-names></name><name><surname>Nomura</surname><given-names>M</given-names></name><name><surname>Abiko</surname><given-names>A</given-names></name><name><surname>Iwashima</surname><given-names>Y</given-names></name><name><surname>Ikoda</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Increased frequency of apolipoprotein epsilon 2 allele in non-insulin dependent diabetic (NIDDM) patients with nephropathy</article-title><source>Clin Genet</source><year>1995</year><volume>48</volume><fpage>288</fpage><lpage>292</lpage><pub-id pub-id-type="pmid">8835322</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chowdhury</surname><given-names>TA</given-names></name><name><surname>Dyer</surname><given-names>PH</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Gibson</surname><given-names>SP</given-names></name><name><surname>Rowe</surname><given-names>BR</given-names></name><name><surname>Davies</surname><given-names>SJ</given-names></name><name><surname>Marshall</surname><given-names>SM</given-names></name><name><surname>Morris</surname><given-names>PJ</given-names></name><name><surname>Gill</surname><given-names>GV</given-names></name><name><surname>Feeney</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Association of apolipoprotein epsilon2 allele with diabetic nephropathy in Caucasian subjects with IDDM</article-title><source>Diabetes</source><year>1998</year><volume>47</volume><fpage>278</fpage><lpage>280</lpage><pub-id pub-id-type="pmid">9519726</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Araki</surname><given-names>S</given-names></name><name><surname>Moczulski</surname><given-names>DK</given-names></name><name><surname>Hanna</surname><given-names>L</given-names></name><name><surname>Scott</surname><given-names>LJ</given-names></name><name><surname>Warram</surname><given-names>JH</given-names></name><name><surname>Krolewski</surname><given-names>AS</given-names></name></person-group><article-title><italic>APOE</italic> polymorphisms and the development of diabetic nephropathy in type 1 diabetes: results of case-control and family-based studies</article-title><source>Diabetes</source><year>2000</year><volume>49</volume><fpage>2190</fpage><lpage>2195</lpage><pub-id pub-id-type="pmid">11118024</pub-id></citation></ref><ref id="B12"><citation citation-type="other"><article-title>Diabetes Mellitus</article-title><source>WHO Technical Report Series 1985, 727 World Health Organization, Geneva</source></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jeppsson</surname><given-names>JO</given-names></name><name><surname>Jerntorp</surname><given-names>P</given-names></name><name><surname>Sundkvist</surname><given-names>G</given-names></name><name><surname>Englund</surname><given-names>H</given-names></name><name><surname>Nylund</surname><given-names>V</given-names></name></person-group><article-title>Measurement of hemoglobin Alc by a new liquid-chromatographic assay: methodology, clinical utility, and relation to glucose tolerance evaluated</article-title><source>Clin Chem</source><year>1986</year><volume>32</volume><fpage>1867</fpage><lpage>1872</lpage><pub-id pub-id-type="pmid">3757206</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marre</surname><given-names>M</given-names></name><name><surname>Claudel</surname><given-names>JP</given-names></name><name><surname>Ciret</surname><given-names>P</given-names></name><name><surname>Luis</surname><given-names>N</given-names></name><name><surname>Suarez</surname><given-names>L</given-names></name><name><surname>Passa</surname><given-names>P</given-names></name></person-group><article-title>Laser immunonephelometry for routine quantification of urinary albumin excretion</article-title><source>Clin Chem</source><year>1987</year><volume>33</volume><fpage>209</fpage><lpage>213</lpage><pub-id pub-id-type="pmid">3802503</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hixson</surname><given-names>JE</given-names></name><name><surname>Vernier</surname><given-names>DT</given-names></name></person-group><article-title>Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal</article-title><source>J Lipid Res</source><year>1990</year><volume>31</volume><fpage>545</fpage><lpage>548</lpage><pub-id pub-id-type="pmid">2341813</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Skobeleva</surname><given-names>NA</given-names></name><name><surname>Vasina</surname><given-names>VI</given-names></name><name><surname>Volkova</surname><given-names>MV</given-names></name><name><surname>Sverdlova</surname><given-names>AM</given-names></name><name><surname>Fomicheva</surname><given-names>EV</given-names></name><name><surname>Obraztsova</surname><given-names>GI</given-names></name><name><surname>Talalaeva</surname><given-names>El</given-names></name><name><surname>Shakir</surname><given-names>K</given-names></name><name><surname>Laasri</surname><given-names>M</given-names></name><name><surname>Vorontsov</surname><given-names>IM</given-names></name><etal></etal></person-group><article-title>DNA polymorphism of the <italic>APOB100, APOCIII, APOE,</italic> and angiotensin-converting enzyme genes and indicators of the lipid spectrum in children and adolescents in St. Petersburg</article-title><source>Mol Gen Mikrobiol Virusol</source><year>1997</year><volume>4</volume><fpage>36</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">9411220</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heesom</surname><given-names>AE</given-names></name><name><surname>Hibberd</surname><given-names>ML</given-names></name><name><surname>Millward</surname><given-names>A</given-names></name><name><surname>Demaine</surname><given-names>AG</given-names></name></person-group><article-title>Polymorphism in the 5'-end of the aldose reductase gene is strongly associated with the development of diabetic nephropathy in type I diabetes</article-title><source>Diabetes</source><year>1997</year><volume>46</volume><fpage>287</fpage><lpage>291</lpage><pub-id pub-id-type="pmid">9000706</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Doria</surname><given-names>A</given-names></name><name><surname>Warram</surname><given-names>JH</given-names></name><name><surname>Krolewski</surname><given-names>AS</given-names></name></person-group><article-title>Genetic predisposition to diabetic nephropathy. Evidence for a role of the angiotensin I &#x02013; converting enzyme gene</article-title><source>Diabetes</source><year>1994</year><volume>43</volume><fpage>690</fpage><lpage>695</lpage><pub-id pub-id-type="pmid">7909524</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ha</surname><given-names>SK</given-names></name><name><surname>Seo</surname><given-names>JK</given-names></name></person-group><article-title>Insertion/deletion polymorphism in <italic>ACE</italic> gene as a predictor for progression of diabetic nephropathy</article-title><source>Kidney Int Suppl</source><year>1997</year><volume>60</volume><fpage>S28</fpage><lpage>S32</lpage><pub-id pub-id-type="pmid">9285899</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fogarty</surname><given-names>DG</given-names></name><name><surname>Zychma</surname><given-names>MJ</given-names></name><name><surname>Scott</surname><given-names>LJ</given-names></name><name><surname>Warram</surname><given-names>JH</given-names></name><name><surname>Krolewski</surname><given-names>AS</given-names></name></person-group><article-title>The C825T polymorphism in the human G-protein beta3 subunit gene is not associated with diabetic nephropathy in Type I diabetes mellitus</article-title><source>Diabetologia</source><year>1998</year><volume>41</volume><fpage>1304</fpage><lpage>1308</lpage><pub-id pub-id-type="pmid">9833937</pub-id><pub-id pub-id-type="doi">10.1007/s001250051069</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Siffert</surname><given-names>W</given-names></name></person-group><article-title>G protein beta3 subunit 825T allele, hypertension, obesity, and diabetic nephropathy</article-title><source>Nephrol Dial Transplant</source><year>2000</year><volume>15</volume><fpage>1298</fpage><lpage>1306</lpage><pub-id pub-id-type="pmid">10978382</pub-id><pub-id pub-id-type="doi">10.1093/ndt/15.9.1298</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shcherbak</surname><given-names>NS</given-names></name><name><surname>Schwartz</surname><given-names>El</given-names></name></person-group><article-title>The C825T polymorphism in the G-protein &#x003b2;3 subunit gene and diabetic complications in IDDM patients</article-title><source>Journal of Human Genetics</source><year>2001</year><volume>46</volume><fpage>188</fpage><lpage>191</lpage><pub-id pub-id-type="pmid">11322658</pub-id><pub-id pub-id-type="doi">10.1007/s100380170087</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shcherbak</surname><given-names>NS</given-names></name><name><surname>Shutskaya</surname><given-names>ZhV</given-names></name><name><surname>Sheidina</surname><given-names>AM</given-names></name><name><surname>Larionova</surname><given-names>VI</given-names></name><name><surname>Schwartz</surname><given-names>El</given-names></name></person-group><article-title>Methylenetetrahydrofolate Reductase Gene Polymorphism as a Risk Factor for Diabetic Nephropathy in IDDM Patients</article-title><source>Molecular Genetics and Metabolism</source><year>1999</year><volume>68</volume><fpage>375</fpage><lpage>378</lpage><pub-id pub-id-type="pmid">10562465</pub-id><pub-id pub-id-type="doi">10.1006/mgme.1999.2909</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>H</given-names></name><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Gejyo</surname><given-names>F</given-names></name><name><surname>Karasawa</surname><given-names>R</given-names></name><name><surname>Miyazaki</surname><given-names>R</given-names></name><name><surname>Suzuki</surname><given-names>S</given-names></name><name><surname>Arakawa</surname><given-names>M</given-names></name></person-group><article-title>Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM</article-title><source>Am J Kidney Dis</source><year>1998</year><volume>31</volume><fpage>666</fpage><lpage>673</lpage><pub-id pub-id-type="pmid">9531184</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tamow</surname><given-names>L</given-names></name><name><surname>Stehouwer</surname><given-names>CD</given-names></name><name><surname>Emeis</surname><given-names>JJ</given-names></name><name><surname>Poirier</surname><given-names>0</given-names></name><name><surname>Cambien</surname><given-names>F</given-names></name><name><surname>Hansen</surname><given-names>BV</given-names></name></person-group><article-title>Parving HH: Plasminogen activator inhibitor-1 and apolipoprotein E gene polymorphisms and diabetic angiopathy</article-title><source>Nephrol Dial Transplant</source><year>2000</year><volume>15</volume><fpage>625</fpage><lpage>630</lpage><pub-id pub-id-type="pmid">10809802</pub-id><pub-id pub-id-type="doi">10.1093/ndt/15.5.625</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Onuma</surname><given-names>T</given-names></name><name><surname>Laffel</surname><given-names>LM</given-names></name><name><surname>Angelico</surname><given-names>MC</given-names></name><name><surname>Krolewski</surname><given-names>AS</given-names></name></person-group><article-title>Apolipoprotein E genotypes and risk of diabetic nephropathy</article-title><source>J Am Soc Nephrol</source><year>1996</year><volume>7</volume><fpage>1075</fpage><lpage>1078</lpage><pub-id pub-id-type="pmid">8829124</pub-id></citation></ref></ref-list></back></article> 